Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
9
×
Tags
boston blog main
boston top stories
9
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
9
×
biotech
crispr
national
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gene editing
glaxosmithkline
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
crispr therapeutics
crispr-cas9
deals
fda
indiana blog main
indiana top stories
startups
biogen
editas medicine
eli lilly
gene therapy
intellia therapeutics
What
crispr
9
×
bio
roundup
cas
editing
gene
medicine
new
today
big
cancer
ceo
editas
human
known
scientists
therapeutics
years
acquisitions
albert
alliance
allogene
available
based
beam
biggest
biopharma
biosciences
bosley's
bosley’s
bourla
bridge
bristol
bucks
buy
calls
cells
changing
cheaper
color
Language
unset
unknown
Current search:
photo
×
" boston top stories "
×
" san francisco top stories "
×
crispr
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M